Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

RAD-140 and Turinabol Interaction: Avoid | Peptide Database

Compound Profiles RAD-140 Selective Androgen Receptor Modulator | Investigational SARM RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist acti

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Turinabol

Oral Anabolic Steroid | Lean Gains & Athletic Performance

Turinabol exerts its anabolic effects through binding to the intracellular androgen receptor (AR), promoting nitrogen retention, protein synthesis, and positive nitrogen balance in skeletal muscle. The 4-chloro substitution on the A-ring is the defining structural feature, serving two key pharmacological purposes: it completely prevents aromatization by the aromatase enzyme (blocking conversion to estrogenic metabolites), and it reduces the compound's androgenic potency relative to its anabolic activity.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take RAD-140 with Turinabol?

Combining RAD-140 with Turinabol is not recommended. Both RAD-140 and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is RAD-140 and Turinabol safe together?

This combination carries significant risk. Both RAD-140 and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between RAD-140 and Turinabol?

Both RAD-140 and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time RAD-140 and Turinabol?

RAD-140 has a half-life of ~60 hours and Turinabol has a half-life of ~16 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Currently in Phase 2 clinical trials for the treatment of androgenetic alopecia. Phase 2a results showed measurable increases in hair count and thickness with the 0.05% topical gel formulation. PP405 directly targets metabolic dormancy in hair follicle stem cells by inhibiting MPC1/MPC2 and promoting anagen re-entry. This mechanism may address follicle miniaturization at an earlier stage than androgen-blocking approaches.

Source: peptide-db.com ↗

Research Indications

First-line pharmacotherapy for type 2 diabetes per ADA/EASD guidelines. Reduces HbA1c by 1.0-1.5% as monotherapy. Proven cardiovascular mortality reduction in the UKPDS trial. Can be used alone or in combination with other antidiabetic agents. Delays or prevents progression from prediabetes to type 2 diabetes. The Diabetes Prevention Program (DPP) showed a 31% reduction in diabetes incidence with metformin compared to placebo over 2.8 years. Particularly effective in younger, more obese individuals. Improves multiple components of metabolic syndrome including fasting glucose, insulin resistance, and visceral adiposity. Often used off-label in non-diabetic individuals with metabolic syndrome who have failed lifestyle interventions. Improves insulin resistance, reduces androgen levels, and may restore ovulatory function in women with PCOS. Used as adjunctive therapy alongside lifestyle modifications. Effectiveness varies and is most pronounced in women with significant insulin resistance. Observational studies suggest diabetic patients on metformin may have lower all-cause mortality than non-diabetic controls. The TAME trial is the first FDA-approved clinical trial to specifically target aging as an indication. Proposed mechanisms include AMPK activation, mTOR inhibition, reduced inflammation, and enhanced autophagy. Multiple observational studies and meta-analyses suggest 20-40% reduced incidence of several cancers (colorectal, breast, prostate, pancreatic) in metformin users versus other antidiabetic therapies. Proposed mechanisms include AMPK-mediated mTOR inhibition and reduced circulating insulin/IGF-1 levels. Prospective clinical trials are ongoing. The UKPDS demonstrated a 39% reduction in myocardial infarction risk in overweight diabetic patients treated with metformin. Mechanisms include improved endothelial function, reduced oxidative stress, and anti-inflammatory effects independent of glucose lowering. Metformin is weight-neutral to mildly weight-reducing, unlike many other diabetes medications. Typical weight loss is 1-3 kg over 6-12 months. May reduce visceral fat preferentially. Often prescribed off-label for weight management in non-diabetic individuals with insulin resistance.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Masteron is administered exclusively via intramuscular injection. Two ester formulations exist: drostanolone propionate, the original pharmaceutical preparation with a short half-life requiring frequent injections (every other day or daily), and drostanolone enanthate, a longer-acting formulation produced by underground labs that permits less frequent dosing (twice weekly). Propionate remains the more widely used and available form. Cutting / Aesthetic Enhancement 300-400 mg/week Every other day (propionate) or 2x per week (enanthate) Intramuscular Contest Preparation 400-500 mg/week Every other day or daily (propionate) AI Replacement / Estrogen Management 200-300 mg/week

Source: peptide-db.com ↗
Potential benefits

What are the cardiovascular benefits of B7-33 compared to other compounds?

B7-33 reduces myocardial fibrosis, enhances vasodilation through nitric oxide pathway, and demonstrates cardioprotective effects in heart failure models. These anti-fibrotic and vasoprotective properties position it for potential use in cardiac remodeling, though all current data is preclinical.

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides